The reiteration of a Buy rating and a maintained price target of $7 by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in the potential growth or recovery of Armata Pharmaceuticals. This endorsement could positively influence investor sentiment and potentially lead to an increase in stock price in the short term.